RP2 + atezolizumab + bevacizumab

About Replimune

Founded in 2015, Replimune is at the forefront of developing next-generation oncolytic immunotherapies with the mission to revolutionize cancer treatment. Its lead candidate, RP1 (vusolimogene odeparepvec), has a PDUFA date of July 22, 2025, for advanced melanoma and is being studied across multiple skin cancers. The company's wholly-owned RPx platform and in-house manufacturing capability position it to develop a broad portfolio of treatments aimed at overcoming resistance to current immunotherapies.

Therapeutic Areas

Other Hepatocellular Carcinoma (HCC) Drugs